Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Intrinsic Value
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. [ Read More ]
The intrinsic value of one
CYCC
stock under the Base Case scenario is
457.29
USD.
Compared to the current market price of 1.75 USD,
Cyclacel Pharmaceuticals Inc
is
Undervalued by 100%.
Cyclacel Pharmaceuticals Inc's market capitalization is 2.3m USD.
CYCC stock price is 1.75 USD.
CYCC stock price (1.75 USD) is 100% less than its Intrinsic Value (457.29 USD).
CYCC stock price (1.75 USD) is 100% less than its Relative Value (464.16 USD). Open Relative Valuation
CYCC.
CYCC's long-term assets (9m USD) exceed its long-term liabilties (8m USD).
CYCC's short-term liabilties (8m USD) exceed its short-term assets (7m USD).
CYCC's ROE (Return on Equity) has significantly decreased in the last 3 years from -50% to -221%, and is approaching profitability.
CYCC's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -311% to -530%, and is approaching profitability.
CYCC has negative Operating Income for the last twelve months.
CYCC has negative Net Income for the last twelve months.
CYCC's ROE (Return on Equity) for the past 12 months is negative and is equal to -221%.
CYCC's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -530%.
CYCC's Revenue is forecast to grow at a rate of 618% per year over the next 3 years.
CYCC has negative Free Cash Flow for the last twelve months.
CYCC has negative three-year average ROE (Return on Equity): -85%. The company is not efficient at transforming stockholders' equity into net income.
CYCC has negative three-year average ROIC (Return on Invested Capital): -470%. The company is not efficient at using invested capital to generate operating income.
CYCC's D/E (Debt to Equity) is very low and is equal to 0.
CYCC's Altman Z-Score is very low and is equal to -9.79.
CYCC doesn't generate enough operating income (-25m USD) to safely cover interest payments on its debt (363k USD).
Fundamental Analysis
Cyclacel Pharmaceuticals Inc
Balance Sheet Decomposition
Cyclacel Pharmaceuticals Inc
| Current Assets | 7.4m |
| Cash & Short-Term Investments | 3.4m |
| Other Current Assets | 4.1m |
| Non-Current Assets | 1.4m |
| PP&E | 102k |
| Other Non-Current Assets | 1.3m |
| Current Liabilities | 8.2m |
| Accounts Payable | 3.5m |
| Accrued Liabilities | 4.6m |
| Non-Current Liabilities | 37k |
| Other Non-Current Liabilities | 37k |
Earnings Waterfall
Cyclacel Pharmaceuticals Inc
|
Revenue
|
420k
USD
|
|
Operating Expenses
|
-25.9m
USD
|
|
Operating Income
|
-25.5m
USD
|
|
Other Expenses
|
2.7m
USD
|
|
Net Income
|
-22.8m
USD
|
Free Cash Flow Analysis
Cyclacel Pharmaceuticals Inc
What is Free Cash Flow?
CYCC Profitability Score
Profitability Due Diligence
Cyclacel Pharmaceuticals Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Cyclacel Pharmaceuticals Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
CYCC Solvency Score
Solvency Due Diligence
Cyclacel Pharmaceuticals Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Cyclacel Pharmaceuticals Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CYCC Price Targets Summary
Cyclacel Pharmaceuticals Inc
Ownership
CYCC Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CYCC Price
Cyclacel Pharmaceuticals Inc
| Average Annual Return | -43.71% |
| Standard Deviation of Annual Returns | 32.19% |
| Max Drawdown | -99% |
| Market Capitalization | 2.3m USD |
| Shares Outstanding | 1 318 260 |
| Percentage of Shares Shorted | 1.95% |
Company Profile
Cyclacel Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Berkeley Heights, New Jersey. The firm is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The firm is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The firm's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The firm's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.
You don't have any saved screeners yet
